NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

生技藥品外包市場-預測(2021年∼2026年)

Biologics Outsourcing Services Market - Forecasts from 2021 to 2026

出版商 Knowledge Sourcing Intelligence 商品編碼 1023148
出版日期 內容資訊 英文 115 Pages
商品交期: 最快1-2個工作天內
價格
生技藥品外包市場-預測(2021年∼2026年) Biologics Outsourcing Services Market - Forecasts from 2021 to 2026
出版日期: 2021年07月06日內容資訊: 英文 115 Pages
簡介

全球生技藥品外包服務市場規模,從2019年的108億7,000萬美元到2026年預計達到261億8,600萬美元,在預期期間中預計以13.38%的年複合成長率成長。

生物製劑本質上是從生物體或由生物體成分組成的藥物。這些藥物進一步用於治療一系列疾病,如慢性病、癌症、心血管疾病等。該市場成長的一個主要原因是生物製劑外包市場對研發的需求不斷成長以及生物療法的進步。隨著研發支出的不斷增加,全球生物製劑外包市場有望成長。

本報告提供全球生技藥品外包市場相關調查,市場概要和各產品,各類型,各來源,各用途,各地區趨勢,及加入此市場的主要企業的簡介等資訊。

目錄

第1章 簡介

  • 市場定義
  • 市場區隔

第2章 調查手法

  • 調查資料
  • 前提條件

第3章 摘要整理

  • 調查、亮點

第4章 市場動態

  • 市場促進因素
  • 市場阻礙因素
  • 波特的五力分析
    • 終端用戶談判力
    • 買方議價能力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係
  • 產業的價值鏈分析

第5章 生技藥品外包服務市場分析:各商品

  • 簡介
  • 抗體
  • 重組蛋白質
  • 疫苗
  • 其他

第6章 生技藥品外包服務市場分析:各用途

  • 簡介
  • 疫苗和治療方法的開發
  • 血液及血液相關產品試驗
  • 細胞及基因治療
  • 組織及組織相關產品試驗
  • 幹細胞調查

第7章 生技藥品的外包服務市場分析:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 其他
  • 中東、非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 台灣
    • 泰國
    • 印尼
    • 其他

第8章 競爭環境與分析

  • 主要企業策略分析
  • 新興企業和市場收益性
  • 企業合併、收購 (M&A)、契約、事業合作
  • 各供應商的競爭力矩陣

第9章 企業簡介

  • Lonza Group Ltd.
  • Charles River Laboratories
  • SGS SA
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec
  • Sartorius AG
  • Catalent, Inc.
  • Boehringer Ingelheim GmbH
  • Toxikon, Inc.
  • Eurofins Scientific SE
目錄
Product Code: KSI061611088

The biologics outsourcing services market is projected to grow at a CAGR of 13.38% to reach US$26.186 billion by 2026 from US$10.870 billion in 2019. Biologics are essentially the drugs procured from living organisms or those which consist of the components of living organisms. These drugs are further used for the treatment of a range of diseases such as chronic diseases, cancer, cardiovascular diseases, etc. They are composed of sugar, proteins, and nucleic acid. When compared to small molecules drugs, biologics are much costlier but provides better results to the patient.

A major reason for the growth of this market is the growing need for research and development in the biologics outsourcing market and the advancement in biologic therapeutics.

The investment in research has increased rapidly. Globally, spending on research and development has increased in the past two decades. Every year the pharmaceutical industry develops a new variety of drugs. Data from the UNESCO Institute for Statistics (UIS) suggests that the global spending on research and development has reached almost US$ 1.7 trillion. According to the World Bank, East Asia and Pacific expenditure on research and development as a percentage of GDP accounts for 2.51 percent. The share of Korea remains the highest (4.81 percent) followed by Japan (3.26 percent) and China (2.19 percent) in the year 2018. In the US alone, pharmaceutical commerce spent $ 83 billion on Research and Development in 2019. According to UNESCO, North America and Western Europe spend the highest in R&D, followed by East Asia, South American, and Africa. Switzerland is the third-largest country to spend on R&D. With an ever-increasing expenditure on research and development, the global biologics outsourcing market is expected to grow.

Biologic therapeutics are considered to be the medicinal solutions of the future. Many countries are working upon the advancement of co-formulation strategies to establish biologic therapeutics. This will increase compliance, convenience, and accordance.

The investment and competition of the biologics outsourcing market are expected to drive the demand for this market in the forecast period.

Several players are making massive investments in the biologics outsourcing market across the world. The biologic outsourcing market is segmented into North America, Europe, Latin America, and the Asia Pacific region. North America is leading the biologic outsourcing market. Owing to a huge investment, wide population, and low-cost drug manufacturing, the Asia-Pacific region prevails as the fastest-growing biologics outsourcing market. With rapidly increasing investment, the European market is also expected to expand.

There's rapidly growing competition in the biologic outsourcing industries. The US owns the largest biologics market. Countries like India and China are providing a competitive edge in terms of lower prices and costs. Some of the leading competitors are Eurofins Scientific SE, WuXi AppTec, Lonza Group Ltd, SGS SA, Etc.

The rising chronic diseases, aging population, and investment are likely to accelerate the global biologics outsourcing market.

According to the world health organization, globally 41 million people die due to chronic diseases. A major proportion of these deaths are accounted to cardiovascular diseases. It claims 17.9 million lives annually, followed by cancer (9 million lives annually), respiratory diseases (3.9 million lives annually), and diabetes (1.6 million lives annually). According to the world health organization, "The number of people aged 65 or older is projected to grow from an estimated 524 million in 2010 to nearly 1.5 billion in 2050, with most of the increase in developing countries." According to the National Institute on Aging, approximately 79 percent of people, aged above 70 years, possess at least one of the seven chronic diseases- heart problem, diabetes, cancer, hypertension, stroke, arthritis, and respiratory disease. The growing number of people suffering from these chronic ailments is expected to drive the biologic outsourcing market. Biologic drugs are considered to be very useful when it comes to treating such diseases. Moreover, the companies are constantly investing in the research and development sector. Biocon Biologics is all set to invest Rupees 555 crores in 2021. Novartis AG, in Singapore, invested USD $700 million in its biologics sector and Squibb invested USD $900 million in 2019.

The rising COVID-19 Cases worldwide are also projected to positively impact the global biologics market.

Apart from social and economic disruptions, the disruption caused in the health care routine of the people by the pandemic is devastating. According to the World Health Organization, "nearly half of the world's 3.3 billion global workforces are at risk of losing livelihoods." This has created distress among the people, thereby having a very bad impact on their health. COVID-19 has also forced health care providers to alter their ways of treating patients. The rate of hospitalization has also increased. As the prolonged spread due to the virus is increasing, the infection spread is treated with biologics. Extensive research is taking place for the same. Until the development of vaccines, the COVID-19 treatment was solely dependent upon biological therapies.

Market Segmentation:

  • By Application

Vaccine and Therapeutics Development

Blood and Blood-Related Products Testing

Cellular and Gene Therapy

Tissue and Tissue-Related Products Testing

Stem Cell Research

  • By Offering

Antibodies

Recombinant Proteins

Vaccines

Others

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • UK
  • Germany
  • France
  • Others

The Middle East and Africa

  • Saudi Arabia
  • UAE
  • Others

Asia Pacific

  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of End-Users
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Biologics Outsourcing Services Market Analysis, by Offering

  • 5.1. Introduction
  • 5.2. Antibodies
  • 5.3. Recombinant Proteins
  • 5.4. Vaccines
  • 5.5. Others

6. Biologics Outsourcing Services Market Analysis, by Application

  • 6.1. Introduction
  • 6.2. Vaccine & Therapeutics Development
  • 6.3. Blood and Blood-Related Products Testing
  • 6.4. Cellular and Gene Therapy
  • 6.5. Tissue and Tissue-Related Products Testing
  • 6.6. Stem Cell Research

7. Biologics Outsourcing Services Market Analysis, by Geography

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. UK
    • 7.4.4. Others
  • 7.5. The Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. Japan
    • 7.6.4. South Korea
    • 7.6.5. Taiwan
    • 7.6.6. Thailand
    • 7.6.7. Indonesia
    • 7.6.8. Others

8. Competitive Environment and Analysis

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. Company Profiles

  • 9.1. Lonza Group Ltd.
  • 9.2. Charles River Laboratories
  • 9.3. SGS SA
  • 9.4. Thermo Fisher Scientific Inc.
  • 9.5. WuXi AppTec
  • 9.6. Sartorius AG
  • 9.7. Catalent, Inc.
  • 9.8. Boehringer Ingelheim GmbH
  • 9.9. Toxikon, Inc.
  • 9.10. Eurofins Scientific SE